Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.

Ataher Q, Portsmouth S, Napolitano LA, Eng S, Greenacre A, Kambugu A, Wood R, Badal-Faesen S, Tressler R.

J Int AIDS Soc. 2012 Jan 26;15(1):2. doi: 10.1186/1758-2652-15-2.

2.

Higher prevalence of predicted X4-tropic strains in perinatally infected older children with HIV-1 subtype C in India.

Neogi U, Sahoo PN, Arumugam K, Sonnerborg A, De Costa A, Shet A.

J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):347-53. doi: 10.1097/QAI.0b013e3182405c7b.

PMID:
22107818
3.

Analysis of HIV tropism in Ugandan infants.

Church JD, Huang W, Mwatha A, Musoke P, Jackson JB, Bagenda D, Omer SB, Donnell D, Nakabiito C, Eure C, Guay LA, Taylor A, Bakaki PM, Matovu F, McConnell M, Fowler MG, Eshleman SH.

Curr HIV Res. 2010 Oct;8(7):498-503.

4.

The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.

Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.

Clin Infect Dis. 2008 May 15;46(10):1617-23. doi: 10.1086/587660.

PMID:
18419499
5.

Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.

Moreno, Clotet, Sarría, Ortega, Leal, Rodriguez-Arrondo, Sánchez-de la Rosa; Allegro Study Group.

HIV Clin Trials. 2009 Nov-Dec;10(6):394-402. doi: 10.1310/hct1006-394.

PMID:
20133270
6.

Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.

Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ.

J Virol. 2007 Aug;81(15):7885-93. Epub 2007 May 16.

7.

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.

PMID:
18614865
8.

Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort.

Kalu AW, Telele NF, Gebreselasie S, Fekade D, Abdurahman S, Marrone G, Sönnerborg A.

BMC Infect Dis. 2017 Jan 6;17(1):37. doi: 10.1186/s12879-016-2163-1.

9.

Co-receptor switch during HAART is independent of virological success.

Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G.

J Med Virol. 2009 Dec;81(12):2036-44. doi: 10.1002/jmv.21598.

PMID:
19856465
10.

HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades.

Gupta S, Neogi U, Srinivasa H, Banerjea AC, Shet A.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):397-404. doi: 10.1097/QAI.0000000000000046.

PMID:
24189148
11.

Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.

Ferrer P, Tello M, Montecinos L, Tordecilla R, Rodríguez C, Beltrán C, Guzmán MA, Ferrés M, Pérez CM, Afani A.

J Clin Virol. 2014 Jul;60(3):290-4. doi: 10.1016/j.jcv.2014.04.004. Epub 2014 Apr 15.

PMID:
24793966
12.

Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism.

Zhang Y, de Lara C, Worth A, Hegedus A, Laamanen K, Beverley P, Macallan D.

PLoS Pathog. 2013;9(4):e1003310. doi: 10.1371/journal.ppat.1003310. Epub 2013 Apr 18.

13.

Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.

Mild M, Kvist A, Esbjörnsson J, Karlsson I, Fenyö EM, Medstrand P.

Infect Genet Evol. 2010 Apr;10(3):356-64. doi: 10.1016/j.meegid.2009.05.003. Epub 2009 May 14.

PMID:
19446658
14.
15.

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2010 Apr;65(4):749-51. doi: 10.1093/jac/dkq029. Epub 2010 Feb 11.

PMID:
20150182
16.

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF.

Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.

PMID:
21349294
17.

A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.

Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL.

PLoS One. 2012;7(9):e46334. doi: 10.1371/journal.pone.0046334. Epub 2012 Sep 27.

18.

HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples.

Lihana RW, Khamadi SA, Lwembe RM, Kinyua JG, Muriuki JK, Lagat NJ, Okoth FA, Makokha EP, Songok EM.

BMC Infect Dis. 2009 Dec 30;9:215. doi: 10.1186/1471-2334-9-215.

19.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.

PMID:
23677920
20.

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.

Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V.

AIDS. 2007 Oct 18;21(16):2243-5.

PMID:
18090053

Supplemental Content

Support Center